For research use only
| Cat No. | ABC-TC0491 |
| Product Type | Human Leukemia Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pleural Effusion |
| Disease | Myeloma |
| Product Code | KARPAS-25; Karpas 25; KARPAS 25; Karpas25 |
KARPAS-25 cell line, derived from human anaplastic large cell lymphoma, serves as a model for studying ALK-positive lymphomas and oncogenic signaling.
KARPAS‑25 is a human plasma cell myeloma cell line derived from the pleural effusion of a 27‑year‑old female patient with plasma cell myeloma, categorized under plasma cell leukemia and multiple myeloma models in cancer cell line databases. These cells exhibit suspension growth with morphology and immunophenotypes characteristic of malignant plasma cells and complex karyotypes involving immunoglobulin heavy chain loci and other aberrations recorded across studied myeloma cell lines. KARPAS‑25 has been included in panels for transcriptomic and genomic analysis, providing a basis for mechanistic studies of plasma cell malignancies and multiple myeloma biology. Specific in vivo metastatic behavior for this line is not broadly defined. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV‑1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | KARPAS-25; Karpas 25; KARPAS 25; Karpas25 |
| Species | Human |
| Cat.No | ABC-TC0491 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pleural Effusion |
| Disease | Myeloma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
KARPAS‑25 is used as an in vitro model of human plasma cell myeloma and plasma cell leukemia for studies of malignant plasma cell proliferation, karyotype aberrations, and gene expression profiles associated with multiple myeloma. It supports analyses of immunoglobulin gene rearrangements, cytokine responses, and mechanisms of drug sensitivity and resistance in plasma cell malignancies, as well as evaluation of targeted therapeutics and signaling pathways implicated in plasma cell survival and progression.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
